Multiple routes of complement activation by Mycobacterium bovis BCG.

Mol Immunol

MRC Immunochemistry Unit, Department of Biochemistry, University of Oxford, Oxford, UK.

Published: October 2009

AI Article Synopsis

  • Mycobacterium tuberculosis, the primary cause of infectious disease globally, can evade the immune system by living inside macrophages after being engulfed.
  • This study focuses on how Mycobacterium bovis BCG activates the complement system, detailing its effects on the classical, alternative, and lectin pathways, which enhance the bacteria's ability to infect macrophages.
  • Findings indicate that activation of the classical pathway can occur with or without antibodies, while the alternative pathway is influenced by Factor H, and specific serum proteins like MBL and L-ficolin bind to the bacteria, leading to further immune activation.

Article Abstract

Mycobacterium tuberculosis is the leading cause of infectious disease in humans in the world. It evades the host immune system by being phagocytosed by macrophages and residing intracellularly. Complement-dependent opsonisation of extracellular mycobacteria may assist them to enter macrophages. This work examines in detail the mechanisms of complement activation by whole mycobacteria using Mycobacterium bovis BCG as a model organism. M. bovis BCG directly activates the classical, lectin and alternative pathways, resulting in fixation of C3b onto macromolecules of the mycobacterial surface. Investigation into the classical pathway has shown direct binding of human C1q to whole mycobacteria in the absence of antibodies. Most human sera contain IgG and IgM-anti-(M. bovis BCG), and pre-incubation with human immunoglobulin enhances C1q binding to the bacteria. Therefore classical pathway activation is both antibody-independent and dependent. The bacteria also activate the alternative pathway in an antibody-independent manner, but Factor H also binds, suggesting some regulation of amplification by this pathway. For the lectin pathway we have demonstrated direct binding of both MBL and L-ficolin from human serum to whole mycobacteria and subsequent MASP2 activation. H-ficolin binding was not observed. No M. bovis BCG cell surface or secreted protease appears likely to influence complement activation. Together, these data provide a more detailed analysis of the mechanisms by which M. bovis BCG interacts with the complement system.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molimm.2009.07.015DOI Listing

Publication Analysis

Top Keywords

bovis bcg
24
complement activation
12
mycobacterium bovis
8
classical pathway
8
direct binding
8
bovis
6
bcg
6
activation
5
pathway
5
multiple routes
4

Similar Publications

Bovine tuberculosis is mainly caused by Mycobacterium bovis. Bacillus Calmette-Guérin (BCG) is an attenuated strain of M. bovis which provides variable disease protection.

View Article and Find Full Text PDF

Background: The increasing prevalence of drug-resistant tuberculosis (TB) underscores the urgent need for novel antimicrobial agents.

Methods: This study integrates cultivation optimization, nuclear magnetic resonance (NMR) fingerprinting, and principal component analysis (PCA) to explore microbial secondary metabolites as potential anti-TB agents.

Results: Using the combined approach, 11 bioactive compounds were isolated and identified, all exhibiting anti- BCG activity.

View Article and Find Full Text PDF

: Immunotherapy is gaining great relevance in both non-muscle-invasive bladder cancer (NMIBC), with the use of bacille Calmette-Guerin (BCG), and in muscle-invasive BC (MIBC) with anti-checkpoint therapies blocking PD-1/PD-L1, CTLA-4/CD80-CD86, and, more recently, NKG2A/HLA-E interactions. Biomarkers are necessary to optimize the use of these therapies. : We evaluated killer-cell immunoglobulin-like receptors (KIRs) and HLA-I genotyping and the expression of NK cell receptors in circulating T and NK lymphocytes at diagnosis in 325 consecutive BC patients (151 treated with BCG and 174 treated with other therapies), as well as in 648 patients with other cancers and 973 healthy donors as controls.

View Article and Find Full Text PDF

Novel target and cofactor repertoire for the transcriptional regulator JTY_0672 from BCG.

Front Microbiol

January 2025

Weifang Key Laboratory of Respiratory Tract Pathogens and Drug Therapy, School of Life Sciences and Technology, Shandong Second Medical University, Weifang, China.

(Mtb) is the pathogenic agent of tuberculosis (TB). Intracellular survival plays a central role in the pathogenesis of Mtb in a manner that is dependent on an array of transcriptional regulators for Mtb. However, the functionality of JTY_0672, a member of the TetR family of transcriptional regulators, remains unknown.

View Article and Find Full Text PDF

Bacillus Calmette-Guerin (BCG) infections following intravesical BCG immunotherapy: a systematic review protocol.

Syst Rev

January 2025

Department of Medicine, Division of Infectious Diseases, Duke University, 148 Hanes House, 315 Trent Dr, Durham, NC, 27710, USA.

Background: Although intravesical Bacillus Calmette-Guerin (BCG) immunotherapy usually exhibits a favorable safety profile, it can lead to the development of BCG infections, both localized and disseminated. Understanding of BCG infections following intravesical BCG immunotherapy is limited because of the lack of consensus definitions of BCG infections and limited post-instillation follow-up. We aim to perform a systematic review of the literature of BCG infections following intravesical BCG immunotherapy to elucidate the epidemiology, risk factors, and outcomes of BCG infections.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!